Meserve J, Facciorusso A, Holmer AK, et al. - Among patients with pre‐existing inflammatory bowel diseases who received immune checkpoint inhibitors, the risks as well as the outcomes of adverse events were analyzed. Researchers identified 12 studies assessing the effect of immune checkpoint inhibitors in 193 patients suffering from inflammatory bowel disease. These studies were identified via a systematic literature review up until July 31, 2020. Among these patients with IBD treated with immune checkpoint inhibitors, relapse was seen in approximately 40%. Most relapsing patients needed corticosteroids (76%) and one‐third needed biologics (37%). Immune checkpoint inhibitors were discontinued by 35% patients with inflammatory bowel disease. A higher risk of relapse may be seen in relation to cytotoxic T‐lymphocyte antigen‐4 inhibitors.